BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 05, 2011
 |  BC Week In Review  |  Company News  |  Other News

Tengion renal, cancer, gene/cell therapy news

Tengion disclosed in its 3Q11 earnings that it will restructure and reduce headcount by 30 (58%) to 22 to fund development of its lead Neo-Urinary Conduit and Neo-Kidney Augment programs through 2012 and to extend its cash through November 2012. The cuts are primarily a result of Tengion's decision to centralize its R&D operations in its Winston-Salem, N.C., facility. Tengion will retain a limited number of...

Read the full 327 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >